Yan Dai, PhD
Assistant Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology Section

PhD, Beijing Medical University
MS, Hebei University



The research interest of my lab is to uncover novel molecular mechanisms regarding cancer cell growth, migration, and invasion in order to develop new strategies for cancer treatment with particular interests in the role of class III HDAC in cancer development and progression. We employ two experimental systems including cultured primary and cancer cell lines, as well as mice models integrated with a number of epigenetic, molecular, and cell biology approaches to pursue in our studies. The current project in my lab includes: 1) Studying the role of SIRT1 in prostate cancer, lung cancer and breast cancer growth, invasion and metastasis. We have established various xenografts mice models, including prostate cancer and breast cancer orthotopic xenografts mice models, experimental metastatic mice models, and subcutaneous mice models. 2) Elucidating the interaction of SIRT1 and RTK signaling pathway in tumor growth and progression. 3) Studying the transcription regulation of tumor suppressor gene expression by histone deacetylase and chromatin remodeling complex. 4) Screening and developing SIRT1 inhibitors as cancer therapeutics.


Boston University Clinical and Translational Science Award (CTSA) Program UL1
05/01/2008 - 04/30/2012 (PI of Sub-Project / SP)
PI: David M. Center, MD
NIH/National Center for Health Research Resources
3UL1RR025771-04

Role of HIC1 in Suppression of Breast Cancer Growth and Tamoxifen Resistance
09/01/2009 - 08/31/2011 (PI)
NIH/National Cancer Institute
5 R21 CA129046 02



Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Dai Y, Sangerman J, Nouraie M, Faller AD, Oneal P, Rock A, Owoyemi O, Niu X, Nekhai S, Maharaj D, Cui S, Taylor R, Steinberg M, Perrine S. Effects of hydroxyurea on F-cells in sickle cell disease and potential impact of a second fetal globin inducer. Am J Hematol. 2017 Jan; 92(1):E10-E11.View Related Profiles. PMID: 27766663; DOI: 10.1002/ajh.24590;.
  2. Cho EH, Dai Y. SIRT1 controls cell proliferation by regulating contact inhibition. Biochem Biophys Res Commun. 2016 Sep 16; 478(2):868-72. PMID: 27514448; DOI: 10.1016/j.bbrc.2016.08.041;.
  3. Boosalis MS, Sangerman JI, White GL, Wolf RF, Shen L, Dai Y, White E, Makala LH, Li B, Pace BS, Nouraie M, Faller DV, Perrine SP. Novel Inducers of Fetal Globin Identified through High Throughput Screening (HTS) Are Active In Vivo in Anemic Baboons and Transgenic Mice. PLoS One. 2015; 10(12):e0144660.View Related Profiles. PMID: 26713848; PMCID: PMC4694699; DOI: 10.1371/journal.pone.0144660;.
  4. Dai Y, Sangerman J, Luo HY, Fucharoen S, Chui DH, Faller DV, Perrine SP. Therapeutic fetal-globin inducers reduce transcriptional repression in hemoglobinopathy erythroid progenitors through distinct mechanisms. Blood Cells Mol Dis. 2016 Jan; 56(1):62-9.View Related Profiles. PMID: 26603726; PMCID: PMC4667977; DOI: 10.1016/j.bcmd.2015.10.004;.
  5. Zhu L, Qi J, Chiao CY, Zhang Q, Porco JA, Faller DV, Dai Y. Identification of a novel polyprenylated acylphloroglucinol-derived SIRT1 inhibitor with cancer-specific anti-proliferative and invasion-suppressing activities. Int J Oncol. 2014 Nov; 45(5):2128-36.View Related Profiles. PMID: 25189993; PMCID: PMC4203335; DOI: 10.3892/ijo.2014.2639;.
  6. Zhu L, Chiao CY, Enzer KG, Stankiewicz AJ, Faller DV, Dai Y. SIRT1 inactivation evokes antitumor activities in NSCLC through the tumor suppressor p27. Mol Cancer Res. 2015 Jan; 13(1):41-9.View Related Profiles. PMID: 25143434; PMCID: PMC4312526; DOI: 10.1158/1541-7786.MCR-14-0239;.
  7. Lovaas JD, Zhu L, Chiao CY, Byles V, Faller DV, Dai Y. SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells. Prostate. 2013 Apr; 73(5):522-30.View Related Profiles. PMID: 23038275; DOI: 10.1002/pros.22592;.
  8. Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, Dai Y. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene. 2012 Oct 25; 31(43):4619-29.View Related Profiles. PMID: 22249256; DOI: 10.1038/onc.2011.612;.
  9. Moore RL, Dai Y, Faller DV. Sirtuin 1 (SIRT1) and steroid hormone receptor activity in cancer. J Endocrinol. 2012 Apr; 213(1):37-48.View Related Profiles. PMID: 22159506; PMCID: PMC3804056; DOI: 10.1530/JOE-11-0217;.
  10. Byles V, Chmilewski LK, Wang J, Zhu L, Forman LW, Faller DV, Dai Y. Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci. 2010; 6(6):599-612.View Related Profiles. PMID: 20941378; PMCID: PMC2952410.
Showing 10 of 18 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 18 publications over 12 distinct years, with a maximum of 2 publications in 2001 and 2008 and 2012 and 2014 and 2015 and 2016

YearPublications
19991
20012
20031
20051
20071
20082
20101
20111
20122
20142
20152
20162
Contact for Mentoring:


72 E. Concord St Instructional (L)
Boston MA 02118
Google Map


Dai's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department